Evidence map›Paper›PMID 36380021›Full record

ReviewNature reviews. Immunology2023

Death by TNF: a road to inflammation.

Geert van Loo, Mathieu J M Bertrand

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 511 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
511citing papers in PubMed, 1 pooled it
65.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

511 citing papers in PubMed, 1 synthesis or guideline pooled it, 807 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Mechanisms, regulation and clinical relevance of necroptosis.Nature reviews. Molecular cell biology · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

451 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Geert van LooCenter for Inflammation Research, VIB, Ghent, Belgium. geert.vanloo@irc.vib-ugent.be.ORCID 0000-0002-8427-4775
Mathieu J M BertrandCenter for Inflammation Research, VIB, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.ORCID 0000-0001-9000-0626
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour necrosis factor (TNF) is a central cytokine in inflammatory reactions, and biologics that neutralize TNF are among the most successful drugs for the treatment of chronic inflammatory and autoimmune pathologies. In recent years, it became clear that TNF drives inflammatory responses not only directly by inducing inflammatory gene expression but also indirectly by inducing cell death, instigating inflammatory immune reactions and disease development. Hence, inhibitors of cell death are being considered as a new therapy for TNF-dependent inflammatory diseases.

Indexed as

InflammationTumor Necrosis Factor-alphaCell DeathCytokinesHumansCytokinesTumor Necrosis Factor-alpha

Identifiers

PMID36380021
PMCPMC9665039
OpenAlexW4309409968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.